Gemcitabine as a radiosensitizer for nonresectable feline oral squamous cell carcinoma

J Am Anim Hosp Assoc. 2003 Sep-Oct;39(5):463-7. doi: 10.5326/0390463.

Abstract

Eight cats with locally advanced, oral squamous cell carcinoma (SCC) were treated with a combination of gemcitabine and palliative radiotherapy. Low-dose gemcitabine was administered twice weekly (25 mg/m2) in conjunction with megavoltage radiation in 6 Gray (Gy) fractions for a total dose of 36 Gy. Responses included two complete and four partial responses, and two cats had no response to therapy. Median duration of remission was 42.5 days (range, 11 to 85 days). Median survival time was 111.5 days (range, 11 to 234 days). This data suggests that a combination of low-dose gemcitabine and palliative radiation therapy may be tolerable for cats with oral SCC and may cause a therapeutic benefit.

Publication types

  • Evaluation Study

MeSH terms

  • Animals
  • Carcinoma, Squamous Cell / drug therapy
  • Carcinoma, Squamous Cell / radiotherapy
  • Carcinoma, Squamous Cell / veterinary*
  • Cat Diseases / drug therapy*
  • Cat Diseases / pathology
  • Cat Diseases / radiotherapy*
  • Cats
  • Combined Modality Therapy
  • Deoxycytidine / administration & dosage*
  • Deoxycytidine / analogs & derivatives*
  • Drug Administration Schedule
  • Female
  • Gemcitabine
  • Male
  • Mouth Neoplasms / drug therapy
  • Mouth Neoplasms / radiotherapy
  • Mouth Neoplasms / veterinary*
  • Palliative Care
  • Radiation-Sensitizing Agents / administration & dosage*
  • Treatment Outcome

Substances

  • Radiation-Sensitizing Agents
  • Deoxycytidine
  • Gemcitabine